Disse stoffers serumkoncentrationer kan stige, når de administreres sammen med lopinavir/ ritonavir, hvilket resulterer i muligheden for forøgning af bivirkninger, som sædvanligvis forbindes med disse cytostatika.
Anticancer agents (eg vincristine, vinblastine): these agents may have their serum concentrations increased when co-administered with lopinavir/ ritonavir resulting in the potential for increased adverse events usually associated with these anticancer agents.